The latest cancer drugs news
Browsing: Cancer Drug News
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
This content is password-protected. To view it, please enter the password below. Password:
SABCS 2023: Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free…
Melanoma and lung cancer drug shows potential in other skin cancer type
Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin,…
Fast-tracked cancer drug candidate causes substantial levels of mutations and must be investigated for risk of secondary cancer
A cancer drug fast-tracked into clinical trials in the United States could be more damaging…
FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
On November 16, 2023, the US Food and Drug Administration approved enzalutamide (Xtandi, Astellas Pharma…
Breast cancer prevention drug approved for post-menopausal women in the UK – here’s how it works
Sarah Allinson, Lancaster University A drug that can halve the risk of developing breast cancer…
Drug shows promise in first-in-human trial for relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center –…
FDA amends pembrolizumab’s gastric cancer indication
On November 7, 2023, the Food and Drug Administration revised the existing indication of pembrolizumab with…
FDA approves pembrolizumab with chemotherapy for biliary tract cancer
On October 31, 2023, the Food and Drug Administration approved pembrolizumab to be used with gemcitabine…
Predicting cancer patient response to drugs that block DNA repair
Testing for genetic biomarkers can predict which cancer patients are likely to benefit from DNA…